|Bid||0.0000 x 1300|
|Ask||0.0000 x 1000|
|Day's Range||2.4400 - 2.4500|
|52 Week Range||1.3300 - 2.7000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CAS Medical is a medical tech company that focuses on non-invasive monitoring of tissue oxygenation in the brain. Edwards will buy CAS Medical in an all-cash transaction for $2.45 per share, or an equity value of about $100 million, according to the terms of the deal.
Tom Patton became the CEO of CAS Medical Systems, Inc. (NASDAQ:CASM) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Post-market close yesterday, CAS Medical (CASM) released preliminary Q4 revenue and monitor placement numbers and provided initial (general) guidance for how they think 2019 may shape up. Note, however, that this current 2019 guidance, of low double-digit FORE-SIGHT sales growth (inline with our prior and current estimates), does not include any potential contribution from their OEM smart cable product – which management now thinks will launch around mid-year. Company guidance will be updated following the launch.
In this article I am going to calculate the intrinsic value of CAS Medical Systems Inc (NASDAQ:CASM) by estimating the company’s future cash flows and discounting them to their present Read More...
Another solid quarter turned in by CAS Medical (CASM) with total revenue jumping 19% yoy and about 2% better than Q2. The combination of revenue growth and effective expense-control initiatives have pushed operating loss lower by an average of ~$150k each quarter since Q1 2017. Importantly, despite the recently instituted trade tariffs, management is guiding for reaching cash flow break even by the end of 2019 (and possibly sooner if the tariffs are lifted).
Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.
The FORE-SIGHT business, particularly as it relates to the U.S. market, continues to impress. The U.S. installed base expanded by 25% yoy during the first half of 2018 and domestic sensor sales have now set new record highs for three consecutive quarters. U.S. FORE-SIGHT revenue grew by an average of 20% yoy over the last three quarters (including 20% in Q2).
Penny stock pickers booked modest returns in these tough conditions, while trend followers and dart throwers took losses. The July penny stock list generated mixed returns, with precious metals and biotech headwinds limiting gains while a mid-month crude oil reversal undermined small energy plays.